Why the study?
Does long-term anticoagulant therapy prevent recurrent VTE in patients with VTE after initial 3 to 6 months of anticoagulation?
Does long-term anticoagulant therapy prevent recurrent VTE in patients with VTE after initial 3 to 6 months of anticoagulation?
This review outlines a clinical approach to the challenging decision of whether to continue anticoagulation indefinitely after an initial 3 to 6 months for VTE, balancing recurrent VTE reduction against major bleeding risks.
Answers are grounded in this paper and cite their sources.
Uncertainty in long-term VTE risks and benefits leaves individualized decisions open; supports decision tools and further evidence generation.
After an initial 3 to 6 months of anticoagulation for venous thromboembolism (VTE), clinicians and patients face an important question: "Do we stop anticoagulants or continue them indefinitely?" The decision is easy in some scenarios (eg, stop in VTE provoked by major surgery). In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them. Once the decision is made to continue, the next question to tackle is "Which anticoagulant?" Here again, it is a difficult decision because of the uncertainty with regard to estimates of efficacy and the safety of anticoagulant options and the tight trade-offs between choices. We conclude with the approach that we take in our clinical practice.
No takes yet. Share an insight, caveat, or question.
Rodger et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: